ClinicaliQ Trial Snapshot
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies — Active Not Recruiting • Phase I • NCT05453903.
- A trial testing a new drug (bleximenib) combined with standard AML treatments to find safe, effective doses.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion). Conditions: Leukemia, Myeloid, Acute Interventions: Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 196 participants